Table 1.

Cell cycle and DNA repair pathway proteins targeting inhibitors in clinical trials for cancer^21,22,23

Inhibitor	Targets	Clinical trials
Flavopiridol
AT7519		Phase I
MK7965		Phase I
AZD 5438		Phase II
R-roscovitine		Phase I
PHA-848125/PHA-848125AC	Pan cdk	Phase I Phase I
PD0332991		Phase III
LY2835219		Phase III
LEE011	CDK-4 and CDK-6	Phase III
PHA-739358		Phase IIand III
MLN8237	Pan AURK AURKA AURKB	Phase II
AZD1152
Rigosertib		Phase II and III Phase II and III
Volasertib	PLK	Phase II
TKM-080301
AZD1775		Phase I and II
MK8776		Phase I and II Phase I and II
LY2606368	CHEK1/CHEK2
ALISERTIB	AURKA	Phase III
ENMD-981693		Phase II
AT-9283		Phase II
TOZASERTIB		Phase II
Danusertib		Phase II
ILORASERTIB		Phase II
TAS-119		Phase I
MK-5108		Phase I
RG-1530		Phase I
CYC-116		Phase I
MLN-8054		Phase I
TTP-607		Phase I
PF-03814735		Phase I
Barasertib	AURKB	Phase III
BI-811283		Phase II
ENMD-2076		Phase II
Chiauranib		Phase I
GSK-1070916		Phase I
MK-6592		Phase I
KW-2449		Phase I
TAK-901		Phase I
AMG-900		Phase I
SNS-314		Phase I
BMS-863233	CDC7	Phase II
NMS-1116354		Phase I
DINACICLIB	CDK1	Phase III
Milciclib		Phase II
AG-24322		Phase I
RGB-286638		Phase I
TG-02		Phase I
AZD-5438		Phase I
SELICICLIB	CDK2	Phase II
RG-547		Phase II
BMS-387032		Phase I
Ribociclib	CDK4	Phase IV
ABEMACICLIB		Phase III
Voruciclib		Phase II
PALBOCICLIB	CDK6	Phase IV
ALVOCIDIB		Phase III
Roniciclib		Phase II
AT-7519		Phase II
UCN-01		Phase II
PHA-793887		Phase I
LY-2606368	CHEK1	Phase II
RABUSERTIB		Phase II
PREXASERTIB		Phase II
RG-7602		Phase I
RG-7741		Phase I
SCH-900776		Phase I
XL-844		Phase I
AZD-7762		Phase I
PF-00477736		Phase I
SODIUM DICHLOROACETATE	PDK1	Phase IV
VOLASERTIB		Phase III
BI-2536		Phase II
MK-1496		Phase I
Cafusertib		Phase I
NMS-1286937		Phase I
TAK-960		Phase I
GSK-461364		Phase I
MIDOSTAURIN	PRKCA	Phase III
SOTRASTAURIN		Phase II
GSK-690693		Phase I